In this non-interventional study, the effectiveness and tolerability of Lusefi® in adult patients with type 2 diabetes will be evaluated.
Men and women aged 18 years and older.
Patients with type 2 diabetes.
Written informed consent of the patient to participate in the study.
No conditions that require emergency medical aid.
Known hypersensitivity to luseogliflozin or other components of Lusefi®.
Type 1 diabetes.
Decompensated type 2 diabetes.
Pregnancy, breastfeeding, or planned pregnancy during the study and at least two months after the study.